In recent years, disease treatment has evolved strategies that require increase in pharmaceutical agent’s efficacy and selectivity while decreasing their toxicity in normal tissues. These requirements have led to the development of nanoscale liposome systems for drug release. This review focuses on lipid features, pharmacological properties of liposomal formulations and the clinical studies of their application. Several lipids are available, but their properties could affect pharmacological or clinical efficiency of drug formulations. Many liposomal formulations have been developed and are currently on the market. Proper selection of lipid is essential for the pharmacological effect to be improved. Most of the formulations use mainly zwitterionic, cationic or anionic lipids, PEG and/or cholesterol, which have different effects on stability, pharmacokinetics and delivery of the drug formulation. Clinical trials have shown that liposomes are pharmacologically and pharmacokinetically more efficient than drug-alone formulations in treating acute myeloid leukemia, hepatitis A, pain management, ovary, gastric breast and lung cancer, among others. Liposomal formulations are less toxic than drugs alone and have better pharmacological parameters. Although they seem to be the first choice for drug delivery systems for various diseases, further research about dosage regimen regarding dose and time needs to be carried out.

中文翻译：

---

纳米医学评论：脂质体应用的临床发展

近年来，疾病治疗已发展出一些策略，需要提高药剂的功效和选择性，同时降低其对正常组织的毒性。这些要求导致了用于药物释放的纳米级脂质体系统的开发。这篇综述着重于脂质特征，脂质体制剂的药理特性及其应用的临床研究。可以使用几种脂质，但是它们的性质可能会影响药物制剂的药理或临床效率。已经开发了许多脂质体制剂，并且目前在市场上。脂质的适当选择是必不可少的药理作用还有待提高。大多数制剂主要使用两性离子，阳离子或阴离子脂质，PEG和/或胆固醇，它们对稳定性有不同的影响，药代动力学和药物制剂的递送。临床试验表明，脂质体在治疗急性髓细胞性白血病，甲型肝炎，疼痛控制，卵巢癌，胃癌和肺癌等方面，在药理和药代动力学上比单纯药物制剂更有效。脂质体制剂比单独的药物毒性低，并且具有更好的药理学参数。尽管它们似乎是用于各种疾病的药物输送系统的首选，但仍需要对有关剂量和时间的剂量方案进行进一步的研究。胃癌和肺癌等。脂质体制剂比单独的药物毒性低，并且具有更好的药理学参数。尽管它们似乎是用于各种疾病的药物输送系统的首选，但仍需要对有关剂量和时间的剂量方案进行进一步的研究。胃癌和肺癌等。脂质体制剂比单独的药物毒性低，并且具有更好的药理学参数。尽管它们似乎是用于各种疾病的药物输送系统的首选，但仍需要对有关剂量和时间的剂量方案进行进一步的研究。